drugset / Trial / NCT00126659
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before and after surgery may be an effective treatment for kidney cancer. This phase II trial is studying how well sorafenib works in treating patients who are undergoing surgery for metastatic kidney cancer.
Timeline
- Start
- 2006-01
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | — | Oral |